Market Cap
US$1.2b
Last Updated
2019/09/20 01:12 UTC
Data Sources
Company Financials +
Executive Summary
Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
Snowflake
Fundamentals
Solid track record with high growth potential.
Similar Companies
Share Price & News
How has Fagron's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-1.0%
ARSU.F
-1.2%
US Healthcare
-0.02%
US Market
1 Year Return
-8.6%
ARSU.F
-9.4%
US Healthcare
1.6%
US Market
ARSU.F matched the Healthcare industry (-9.4%) over the past year.
ARSU.F underperformed the Market in United States of America which returned 1.6% over the past year.
Share holder returns
| ARSU.F | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.0% | -1.2% | -0.02% |
| 30 Day | n/a | -2.2% | 2.7% |
| 90 Day | n/a | -1.5% | 1.4% |
| 1 Year | -8.6%-8.6% | -8.0%-9.4% | 3.8%1.6% |
| 3 Year | n/a | 28.7%23.5% | 45.2%35.8% |
| 5 Year | -69.6%-69.6% | 62.7%53.0% | 61.8%44.1% |
Price Volatility Vs. Market
How volatile is Fagron's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Fagron undervalued based on future cash flows and its price relative to the stock market?
37%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Fagron's share price is below the future cash flow value, and at a moderate discount (> 20%).
Fagron's share price is below the future cash flow value, but not at a substantial discount (< 40%).
Price Based on Earnings
Fagron is overvalued based on earnings compared to the US Healthcare industry average.
Fagron is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Fagron is poor value based on expected growth next year.
Price Based on Value of Assets
Fagron is overvalued based on assets compared to the US Healthcare industry average.
Next Steps
Future Growth
How is Fagron expected to perform in the next 1 to 3 years based on estimates from 5 analysts?
22.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Fagron's revenue is expected to grow by 8% yearly, however this is not considered high growth (20% yearly).
Fagron's earnings are expected to grow significantly at over 20% yearly.
Fagron's revenue growth is expected to exceed the United States of America market average.
Fagron's earnings growth is expected to exceed the United States of America market average.
Fagron's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Fagron is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
Next Steps
Past Performance
How has Fagron performed over the past 5 years?
13.2%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Fagron's year on year earnings growth rate has been positive over the past 5 years.
Fagron's 1-year earnings growth exceeds its 5-year average (14% vs 13.2%)
Fagron's earnings growth has exceeded the US Healthcare industry average in the past year (14% vs 5.6%).
Return on Equity
Whilst Fagron has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.
Return on Assets
Fagron used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.
Return on Capital Employed
Fagron has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Fagron's financial position?
Financial Position Analysis
Fagron is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Fagron's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Fagron's level of debt (154.8%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (341.6% vs 154.8% today).
Debt is well covered by operating cash flow (22.6%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 11.2x coverage).
Balance Sheet
High level of physical assets or inventory.
Debt is not covered by short term assets, assets are 0.7x debt.
Next Steps
Dividend
What is Fagron's current dividend yield, its reliability and sustainability?
1.11%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Fagron's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
Fagron's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).
Fagron is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
Fagron is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to Shareholders
No need to calculate the sustainability of Fagron's dividends as it is not paying a notable one for United States of America.
Future Payout to Shareholders
Dividends after 3 years are expected to be well covered by earnings (5.2x coverage).
Next Steps
Management
What is the CEO of Fagron's salary, the management and board of directors tenure and is there insider trading?
1.7yrs
Average management tenure
CEO
Rafael Padilla (41yo)
1.8yrs
Tenure
€742,000
Compensation
Mr. Rafael Padilla has been Chief Executive Officer at Fagron NV since November 27, 2017 and served as its Area General Manager of South America and Southern Europe since October 25, 2016. Mr. Padilla serv ...
CEO Compensation Analysis
Rafael's remuneration is lower than average for companies of similar size in United States of America.
Rafael's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
Management Age and Tenure
1.7yrs
Average Tenure
41yo
Average Age
The average tenure for the Fagron management team is less than 2 years, this suggests a new team.
Board Age and Tenure
2.9yrs
Average Tenure
46yo
Average Age
The average tenure for the Fagron board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Céline Caveye
Global HR Director
- Tenure: 1.7yrs
Constantijn Rietschoten (49yo)
Chief Communications Officer
- Tenure: 0yrs
Tomasz Kania
Chief Operations Officer
- Tenure: 1.6yrs
Karin de Jong (40yo)
CFO & Executive Director
- Tenure: 2.9yrs
Rafael Padilla (41yo)
CEO & Director
- Tenure: 1.8yrs
- Compensation: €742.00k
Blake Keller
President of North America
- Tenure: 0yrs
Johan Verlinden
Global Legal Affairs Director
- Tenure: 1.7yrs
Baris Arican
Chief Information Officer
- Tenure: 0yrs
Board Members
Marc Armand Alice André Coucke (54yo)
Non Executive Director
- Tenure: 2.9yrs
- Compensation: €30.00k
Frank Vlayen (54yo)
Non-Executive Director
- Tenure: 0yrs
- Compensation: €37.20k
Veerle Deprez (59yo)
Independent Director
- Tenure: 2.3yrs
- Compensation: €30.00k
Michael Schenck (37yo)
Non-Executive Director
- Tenure: 0yrs
- Compensation: €37.20k
Marc Janssens (60yo)
Non Executive Director
- Tenure: 2.9yrs
- Compensation: €30.00k
Giulia Van Waeyenberge (37yo)
Independent Director
- Tenure: 3.1yrs
- Compensation: €37.20k
Koen Hoffman (51yo)
Chairman
- Tenure: 2.3yrs
- Compensation: €100.00k
Karin de Jong (40yo)
CFO & Executive Director
- Tenure: 2.9yrs
Rafael Padilla (41yo)
CEO & Director
- Tenure: 1.8yrs
- Compensation: €742.00k
Matthias Geyssens (35yo)
Non-Executive Director
- Tenure: 0yrs
- Compensation: €37.20k
Company Information
Fagron NV's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fagron NV
- Ticker: ARSU.F
- Exchange: OTCPK
- Founded: 1990
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: €1.175b
- Listing Market Cap: €1.299b
- Shares outstanding: 71.74m
- Website: https://www.fagron.com
Number of Employees
Location
- Fagron NV
- Venecoweg 20A
- Nazareth
- East Flanders
- 9810
- Belgium
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 4A5 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Oct 2007 |
| FAGR | ENXTBR (Euronext Brussels) | Yes | Ordinary Shares | BE | EUR | Oct 2007 |
| 0HNZ | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Oct 2007 |
| FAGRB | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Oct 2007 |
| ARSU.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Oct 2007 |
Biography
Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates through four segments: Fagron Europe, Fagro ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/20 01:12 |
| End of Day Share Price | 2019/09/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.